Vivalis SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Biodiem Ltd Announces successful Results From Two Programs Of Work Carried Out By French Partner Vivalis SA
Biodiem Ltd announced successful results from two programs of work carried out by French partner Vivalis SA, confirming the ability of BioDiem's Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS' EB66 cell line. The next stage of the collaboration between BioDiem and VIVALIS will use known techniques to modify the LAIV virus to demonstrate and optimize the methodology for making a customizable “vector” which could be used by vaccine developers for the development of new vaccines targeting other specific diseases. Priority disease targets include nasopharyngeal carcinoma and respiratory syncytial virus infection. The results are significant for both companies, as both the BioDiem LAIV virus and the VIVALIS EB66 cell line have been used to produce vaccines that have been tested in successful Phase II clinical trials. The resulting human safety data will facilitate a shorter and lower cost path to commercialisation on completion of the next stage of development with Vivalis. VIVALIS undertook this research based on the high potential value of BioDiem’s technology in non-influenza vaccine applications, both therapeutic and preventative. This work has confirmed the successful and abundant growth of LAIV in VIVALIS’ EB66 cell line. The next step will be the development of a stable LAIV vector technology which uses EB66 as a base platform for growth.
Latest Developments for Valneva SE
- Valneva SE Confirms FY 2013 Revenue Guidance in Line with Analysts' Estimates
- Valneva SE Provides Update on Phase II/III Interim Analysis of Its Pseudomonas Aeruginosa Vaccine Candidate
- Valneva SE Wins FDA Market Exclusivity for the Pediatric Indication of IXIARO in the United States
- Valneva SE Issues FY 2013 Revenue and Grants Guidance
- Share this
- Digg this